ATE279441T1 - Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen - Google Patents

Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen

Info

Publication number
ATE279441T1
ATE279441T1 AT01130805T AT01130805T ATE279441T1 AT E279441 T1 ATE279441 T1 AT E279441T1 AT 01130805 T AT01130805 T AT 01130805T AT 01130805 T AT01130805 T AT 01130805T AT E279441 T1 ATE279441 T1 AT E279441T1
Authority
AT
Austria
Prior art keywords
production
genetically modified
heterologue
binding proteins
precursor cells
Prior art date
Application number
AT01130805T
Other languages
English (en)
Inventor
Ulf Grawunder
Georg Friedrich Melchers
Original Assignee
4Antibody Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Antibody Ag filed Critical 4Antibody Ag
Application granted granted Critical
Publication of ATE279441T1 publication Critical patent/ATE279441T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT01130805T 2001-12-22 2001-12-22 Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen ATE279441T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20010130805 EP1321477B1 (de) 2001-12-22 2001-12-22 Verfahren zur Herstellung von genetisch veränderten Lymphozyten Vorläuferzellen von Wirbeltieren und deren Gebrauch zur Produktion von heterologen Bindeproteinen

Publications (1)

Publication Number Publication Date
ATE279441T1 true ATE279441T1 (de) 2004-10-15

Family

ID=8179695

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01130805T ATE279441T1 (de) 2001-12-22 2001-12-22 Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen

Country Status (5)

Country Link
EP (1) EP1321477B1 (de)
AT (1) ATE279441T1 (de)
DE (1) DE60106469T2 (de)
DK (1) DK1321477T3 (de)
ES (1) ES2231382T3 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2425240A4 (de) 2009-04-30 2012-12-12 Good Start Genetics Inc Verfahren und zusammensetzung zur bewertung genetischer marker
US12129514B2 (en) 2009-04-30 2024-10-29 Molecular Loop Biosolutions, Llc Methods and compositions for evaluating genetic markers
CA2809089C (en) 2010-08-23 2018-12-18 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
US9163281B2 (en) 2010-12-23 2015-10-20 Good Start Genetics, Inc. Methods for maintaining the integrity and identification of a nucleic acid template in a multiplex sequencing reaction
CA2852665A1 (en) 2011-10-17 2013-04-25 Good Start Genetics, Inc. Analysis methods
CN107858333B (zh) * 2011-10-28 2022-05-27 瑞泽恩制药公司 T细胞受体基因修饰小鼠
US8209130B1 (en) 2012-04-04 2012-06-26 Good Start Genetics, Inc. Sequence assembly
US8812422B2 (en) 2012-04-09 2014-08-19 Good Start Genetics, Inc. Variant database
US10227635B2 (en) 2012-04-16 2019-03-12 Molecular Loop Biosolutions, Llc Capture reactions
CA2888779A1 (en) * 2012-11-07 2014-05-15 Good Start Genetics, Inc. Validation of genetic tests
EP2971159B1 (de) 2013-03-14 2019-05-08 Molecular Loop Biosolutions, LLC Verfahren zur analyse von nukleinsäuren
WO2014197377A2 (en) 2013-06-03 2014-12-11 Good Start Genetics, Inc. Methods and systems for storing sequence read data
EP3058096A1 (de) 2013-10-18 2016-08-24 Good Start Genetics, Inc. Verfahren zur beurteilung eines genomischen bereichs einer person
US10851414B2 (en) 2013-10-18 2020-12-01 Good Start Genetics, Inc. Methods for determining carrier status
US11053548B2 (en) 2014-05-12 2021-07-06 Good Start Genetics, Inc. Methods for detecting aneuploidy
WO2016025818A1 (en) 2014-08-15 2016-02-18 Good Start Genetics, Inc. Systems and methods for genetic analysis
WO2016040446A1 (en) 2014-09-10 2016-03-17 Good Start Genetics, Inc. Methods for selectively suppressing non-target sequences
JP2017536087A (ja) 2014-09-24 2017-12-07 グッド スタート ジェネティクス， インコーポレイテッド 遺伝子アッセイのロバストネスを増大させるためのプロセス制御
WO2016112073A1 (en) 2015-01-06 2016-07-14 Good Start Genetics, Inc. Screening for structural variants
EP4628587A3 (de) 2016-04-15 2026-02-25 Memorial Sloan Kettering Cancer Center Transgene t-zelle und chimäre antigenrezeptor-t-zellzusammensetzungen sowie zugehörige verfahren

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE158021T1 (de) * 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO2001087058A1 (en) * 2000-05-15 2001-11-22 Sonoko Habu Chimeric mouse having immunity constructed by using human cd34-positive cells and use thereof

Also Published As

Publication number Publication date
EP1321477A1 (de) 2003-06-25
DE60106469D1 (de) 2004-11-18
EP1321477B1 (de) 2004-10-13
ES2231382T3 (es) 2005-05-16
DE60106469T2 (de) 2005-10-13
DK1321477T3 (da) 2005-02-14

Similar Documents

Publication Publication Date Title
ATE279441T1 (de) Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen
ATE464373T1 (de) Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung
ATE358730T1 (de) Einzelketten vhh antikörper aus kamelen, verfahren zur deren herstellung in einem saugetier und deren verwendungen
ATE405644T1 (de) Verfahren zur herstellung und reinigung von erythropoietin
DE69925856D1 (de) Verfahren zur klonierung von schweinen
DE69841251D1 (de) Vesikuläre komplexe und verfahren zu deren herstellung und verwendung
ATE170630T1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
ATE414162T1 (de) Verfahren und materialien zur herstellung von glucosamin
DE69830315D1 (de) Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
ATE309196T1 (de) Verfahren zur herstellung von 3-aryloxy-3- arylpropylamine und deren zwischenprodukte
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
ATE449850T1 (de) Mutanten von flt3-l und ihre verwendungen
ATE161041T1 (de) Verfahren zur hcv-züchtung in zell-linien aus b- oder t-lymphozyten
DE60121928D1 (de) Verfahren zur herstellung von den trans-4-n-butylcyclohexanoicsaüre- und undecanoicsaüreestern von (7-alpha,11-beta)-dimethyl-17 beta -hydroxy-4-estren-3-one und deren medizynische anwendung
ES2185146T3 (es) Receptores de netrina.
DE10390418D2 (de) Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
DE60102147D1 (de) Anti-gefrier proteine, deren herstellung und verwendung
ATE328102T1 (de) Verfahren zur herstellung von proteine
DE69430975D1 (de) Verfahren zur Herstellung von Proteinen
DE69637154D1 (de) Hocheffizientes gewebespezifisches system zur bereitstellung von verbindungen unter verwendung eines streptavidin-protein a fusionsproteins
PL367306A1 (pl) Szczepionki na bazie autologicznych komórek T i sposoby ich otrzymywania
ATE332905T1 (de) Verfahren zur herstellung von acylphosphinoxiden
DE3786673D1 (de) Verfahren zur entfernung unerwuenschter zellen aus menschlichen lymphozytenpopulationen, anwendung des verfahrens zur herstellung monoklonaler antikoerper und dafuer geeigneter kit.
ATE216778T1 (de) Verfahren zur herstellung von konjugaten aus einem spezifischen bindungspartner und einem kohlenhydrathaltigen protein

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1321477

Country of ref document: EP